Shares of argenx SE (NASDAQ:ARGX – Get Free Report) have earned a consensus rating of “Moderate Buy” from the nineteen ratings firms that are covering the stock, MarketBeat.com reports. One analyst has rated the stock with a sell recommendation, two have given a hold recommendation and sixteen have assigned a buy recommendation to the company. The average 12 month price objective among brokerages that have updated their coverage on the stock in the last year is $547.11.
ARGX has been the topic of several research analyst reports. Piper Sandler raised their price objective on shares of argenx from $595.00 to $600.00 and gave the stock an “overweight” rating in a research note on Thursday, August 31st. Jefferies Financial Group upped their price target on argenx from $605.00 to $628.00 in a report on Monday, October 2nd. Truist Financial reissued a “buy” rating and set a $570.00 price objective on shares of argenx in a report on Wednesday, November 1st. Scotiabank started coverage on argenx in a research note on Monday, July 31st. They issued a “sector perform” rating and a $516.00 target price for the company. Finally, Wells Fargo & Company lifted their price target on shares of argenx from $606.00 to $609.00 and gave the stock an “overweight” rating in a research note on Friday, July 28th.
Institutional Inflows and Outflows
argenx Price Performance
NASDAQ ARGX opened at $489.77 on Friday. The firm has a market capitalization of $28.94 billion, a PE ratio of -117.73 and a beta of 0.79. argenx has a 12 month low of $333.07 and a 12 month high of $550.76. The company’s 50 day simple moving average is $493.30 and its 200 day simple moving average is $460.93.
argenx (NASDAQ:ARGX – Get Free Report) last issued its earnings results on Tuesday, October 31st. The company reported ($1.25) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($1.48) by $0.23. argenx had a negative return on equity of 12.40% and a negative net margin of 22.70%. The business had revenue of $339.84 million for the quarter, compared to analysts’ expectations of $310.06 million. During the same period in the previous year, the firm posted ($4.26) EPS. Sell-side analysts anticipate that argenx will post -4.76 earnings per share for the current fiscal year.
argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, the Netherlands, Belgium, Japan, Switzerland, Germany, France, Canada, the United Kingdom, and Italy. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, pemphigus foliaceus, chronic inflammatory demyelinating polyneuropathy, bullous pemphigoid, and idiopathic inflammatory myopathy; and ENHANZE SC.
- Five stocks we like better than argenx
- How to Read Stock Charts for Beginners
- S&P 500’s Whirlwind: Big gains, warning whispers & tactical moves
- Most active stocks: Dollar volume vs share volume
- MarketBeat Week in Review – 11/13 – 11/17
- How the NYSE and NASDAQ are Different, Why That Matters to Investors
- 3 large caps with red hot RSIs with upside
Receive News & Ratings for argenx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for argenx and related companies with MarketBeat.com's FREE daily email newsletter.